Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADEL-101
- Development stage
- Preclinical
- Lead developer
- Aptadel Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Natural RNA Aptamers → RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
ADEL-101 is an RNA-based aptamer-drug conjugate developed by Aptadel Therapeutics for the treatment of Ewing sarcoma, a rare and aggressive pediatric cancer. The drug consists of an RNA aptamer that specifically targets the Ephrin type-A receptor 2 (EphA2) on tumor cells, conjugated to a small interfering RNA (siRNA) designed to silence EWS/FLI1, the main oncogenic fusion driver in Ewing sarcoma. This dual mechanism aims to inhibit both tumor proliferation and metastatic potential. Preclinical studies have demonstrated high specificity for tumor targeting, significant reduction in tumor growth and metastasis in animal models, and a favorable safety profile with no observed toxicity at maximum tolerated doses. The platform technology underlying ADEL-101 may also be applicable to other cancers[1][3][4].
- Other names
- ADEL 101ADEL101ADEL-101
02
Targets
EWS-FLI1 (Ewing sarcoma breakpoint region 1–Friend leukemia virus integration 1 fusion protein)EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on ADEL-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADEL-101.